secwatch.observer — SEC 8-K summary
======================================

Issuer:     ALNYLAM PHARMACEUTICALS, INC. (ALNY)
CIK:        0001178670
Form:       8-K
Filed at:   2025-12-03T23:59:59+00:00
Accession:  0001628280-25-055084
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alnylam board changes: Bonney and Bertozzi resign; Arbuckle appointed director
------------------------------------------------------------------------------

- Mike Bonney and Carolyn Bertozzi resigned from Alnylam board effective Dec 2, 2025; no disagreement with company.
- Bertozzi resigned due to election to Eli Lilly board (eff. Dec 8, 2025); will continue as scientific advisor.
- Stuart Arbuckle (ex-Vertex COO) elected to board, effective Jan 5, 2026; receives $75K annual cash retainer plus stock.
- Board size reduced from 11 to 10 following resignations; Arbuckle serves as Class I director until 2026 annual meeting.
- Arbuckle brings commercial and leadership experience from GSK, Amgen, and Vertex; also serves on Rhythm Pharma board.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1178670/000162828025055084/0001628280-25-055084-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1178670/000162828025055084/alny-20251202.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-055084

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer